Načítá se...
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an app...
Uloženo v:
| Vydáno v: | Oncol Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Healthcare
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315076/ https://ncbi.nlm.nih.gov/pubmed/28261647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0028-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|